Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.63 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.59 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 12/20 | 0.53 |
| ▸ | RAB9A | P51151 | 9/20 | 0.52 |
| ▸ | NPC1 | O15118 | 8/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.52 |
| ▸ | RELA | Q04206 | 5/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2360965 | 0.79 | NPC1 (0.51) | SMN1; SMN2RAB9ANPC1L3MBTL1MAPT | |
| SCHEMBL2359855 | 0.79 | NOTUM (0.56) | NR1H4NOTUMSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2090310 | 0.77 | RAB9A (0.61) | SMN1; SMN2RAB9ANPC1NFKB1NFKB2 | |
| SCHEMBL2360818 | 0.77 | TP53 (0.56) | SMN1; SMN2RAB9ANPC1L3MBTL1TP53 | |
| SCHEMBL1473020 | 0.77 | NR1H4 (1.00) | NR1H4NOTUMGPR55SMN1; SMN2RAB9A | |
| SCHEMBL3770905 | 0.76 | NR1H4 (0.65) | NR1H4NOTUMGPR55SMN1; SMN2RAB9A | |
| SCHEMBL5661093 | 0.75 | RAB9A (0.61) | NR1H4SMN1; SMN2RAB9ANPC1NFKB1 | |
| SCHEMBL8830004 | 0.75 | NPC1 (0.59) | SMN1; SMN2RAB9ANPC1L3MBTL1MAPT | |
| SCHEMBL7958860 | 0.74 | SMN1; SMN2 (0.65) | NR1H4NOTUMGPR55SMN1; SMN2RAB9A | |
| SCHEMBL255502 | 0.74 | L3MBTL1 (0.74) | NR1H4NOTUMGPR55SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2999338-B1 | KNOWN AND NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2017-07-12 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | NR1H4 446/4885NOTUM 4043/4885GPR55 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.